Perpetual Ltd Increases Stock Position in Bristol Myers Squibb Company $BMY

Perpetual Ltd increased its holdings in shares of Bristol Myers Squibb Company (NYSE:BMY) by 121.2% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 66,741 shares of the biopharmaceutical company’s stock after purchasing an additional 36,562 shares during the period. Perpetual Ltd’s holdings in Bristol Myers Squibb were worth $3,600,000 as of its most recent SEC filing.

Other large investors also recently bought and sold shares of the company. Relyea Zuckerberg Hanson LLC purchased a new stake in Bristol Myers Squibb during the fourth quarter worth $218,000. Sheets Smith Wealth Management increased its holdings in shares of Bristol Myers Squibb by 11.2% in the 4th quarter. Sheets Smith Wealth Management now owns 5,129 shares of the biopharmaceutical company’s stock valued at $277,000 after acquiring an additional 518 shares during the period. Global Trust Asset Management LLC raised its position in shares of Bristol Myers Squibb by 2,916.2% in the 4th quarter. Global Trust Asset Management LLC now owns 27,176 shares of the biopharmaceutical company’s stock worth $1,466,000 after acquiring an additional 26,275 shares in the last quarter. Thurston Springer Miller Herd & Titak Inc. lifted its stake in shares of Bristol Myers Squibb by 4,367.5% during the 4th quarter. Thurston Springer Miller Herd & Titak Inc. now owns 1,787 shares of the biopharmaceutical company’s stock worth $96,000 after purchasing an additional 1,747 shares during the last quarter. Finally, SteelPeak Wealth LLC purchased a new stake in shares of Bristol Myers Squibb during the 4th quarter worth $1,961,000. Institutional investors own 76.41% of the company’s stock.

Bristol Myers Squibb Stock Down 0.0%

BMY stock opened at $59.57 on Friday. The stock has a market capitalization of $121.63 billion, a PE ratio of 17.27, a price-to-earnings-growth ratio of 0.17 and a beta of 0.27. Bristol Myers Squibb Company has a 52 week low of $42.52 and a 52 week high of $62.89. The company has a quick ratio of 1.14, a current ratio of 1.26 and a debt-to-equity ratio of 2.32. The firm has a 50 day moving average of $59.37 and a 200 day moving average of $52.70.

Bristol Myers Squibb (NYSE:BMY) last issued its quarterly earnings results on Thursday, February 5th. The biopharmaceutical company reported $1.26 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.65 by ($0.39). Bristol Myers Squibb had a net margin of 14.64% and a return on equity of 69.65%. The company had revenue of $12.50 billion for the quarter, compared to analyst estimates of $12.24 billion. During the same quarter in the previous year, the company posted $1.67 EPS. The company’s revenue for the quarter was up 1.3% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. Sell-side analysts forecast that Bristol Myers Squibb Company will post 6.74 earnings per share for the current year.

Bristol Myers Squibb Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, May 1st. Shareholders of record on Thursday, April 2nd will be given a dividend of $0.63 per share. The ex-dividend date of this dividend is Thursday, April 2nd. This represents a $2.52 dividend on an annualized basis and a yield of 4.2%. Bristol Myers Squibb’s payout ratio is currently 73.04%.

Insider Buying and Selling

In other Bristol Myers Squibb news, EVP David V. Elkins sold 30,000 shares of the business’s stock in a transaction dated Wednesday, April 1st. The stock was sold at an average price of $61.67, for a total transaction of $1,850,100.00. Following the sale, the executive vice president owned 159,248 shares in the company, valued at approximately $9,820,824.16. The trade was a 15.85% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 0.09% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on BMY shares. Piper Sandler reiterated an “overweight” rating and issued a $75.00 target price (up from $66.00) on shares of Bristol Myers Squibb in a research note on Monday, February 23rd. Royal Bank Of Canada began coverage on shares of Bristol Myers Squibb in a research report on Tuesday, February 24th. They set a “sector perform” rating and a $60.00 target price for the company. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Bristol Myers Squibb in a report on Monday, March 23rd. Citigroup upped their price target on Bristol Myers Squibb from $60.00 to $64.00 and gave the stock a “neutral” rating in a research report on Friday, February 6th. Finally, Bank of America raised Bristol Myers Squibb from a “neutral” rating to a “buy” rating and raised their price objective for the stock from $52.00 to $61.00 in a research report on Monday, December 15th. Nine research analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $61.41.

Key Stories Impacting Bristol Myers Squibb

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Positive Phase‑3 data for Camzyos in the SCOUT‑HCM adolescent trial could expand the label and support longer‑term revenue upside. SCOUT‑HCM Trial Results
• Positive Sentiment: Janux Therapeutics triggered a $35M milestone under its collaboration with BMY by nominating a development candidate — near‑term cash and partner validation for BMY’s partnered R&D. Janux Milestone
• Positive Sentiment: Unusually large call‑option activity (~66,900 calls) signals speculative bullish positioning by traders anticipating upside moves. Call Option Activity
• Positive Sentiment: Analyst pieces and screens highlight BMY’s history of earnings surprises and argue the company has components that could support an earnings beat next quarter — a sentiment tailwind if results improve. Zacks Coverage
• Neutral Sentiment: Market estimates and long‑term market studies (e.g., HNSCC market growth to ~ $4.5B by 2034) provide attractive addressable‑market context but aren’t immediate catalysts. HNSCC Market Outlook
• Neutral Sentiment: Brokerage consensus remains centered on a “Hold” and the street target (~$61.41) is close to the current price — keeps upside expectations measured. Analyst Consensus
• Negative Sentiment: Insider selling: EVP David V. Elkins sold 30,000 shares at about $61.67 on April 1 (Form 4), trimming his stake ~15.9% — investors sometimes read executive sales as a near‑term negative signal. Insider Form 4
• Negative Sentiment: Sector risk: reports that the U.S. may consider heavy tariffs (up to 100%) on branded/patented drug imports sparked broad healthcare selling and pressured BMY along with peers. Tariffs / Sector Selloff
• Negative Sentiment: Recent quarterly results showed an EPS miss (Feb. 5), which keeps investor focus on near‑term profitability despite FY‑26 guidance; that remains a headwind until earnings execution improves. Earnings Recap

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.